Epilepsy Drug Market

The global epilepsy drug market size is projected to register a substantial CAGR during the forecast period, 2021-2018. The growth of the market is attributed to the anticipated launch of epilepsy drugs that are currently in the pipeline. The growth of the market is also attributed to the global increasing incidence of epilepsy cases along with the rising demand for third-generation anti-epileptics.

Get Free Sample Report

Epilepsy is one of the most common disorders in which the brain’s nerve cell activity gets disturbed and causes seizures. Epilepsy is expected to occur when an individual acquires some brain injury such as stroke or trauma. It can also occur due to some genetic disorder. When an individual suffers from epilepsy their brain activity becomes abnormal which leads to loss of awareness, sensations, and behaving unusually. Epilepsy cannot be cured but can be controlled with the usage of drugs. Change in diet, devices, and surgery are also done in some cases to treat epilepsy. As per the reports by the Epilepsy Foundation of America, there are 65 million individuals are suffering from epilepsy across the globe among which the U.S, alone have 3.4 million individuals who develop epilepsy at some point in their life. Every year 150,000 new cases are registered in the U.S.

The COVID-19 pandemic had adverse impact on the epilepsy market as the development of epilepsy drugs for the treatment was severely disturbed due to sudden halt of the manufacturing units. Meanwhile, it is not sure whether epilepsy increase the risk of getting infected with COVID-19. No evidence is available that proves that people suffering from epilepsy have a weak immune system. However, there may be some factors that are anticipated to affect the immune system and increase the chances of being affected by COVID-19.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing approvals of new drugs for the treatment of epilepsy in the past few years is a key factor driving the market growth expansion during the forecast period.
• Availability of healthcare infrastructure in the developed region is another factor helping the market growth in the coming years.
• Side effects caused due to the consumption of epilepsy drugs are estimated to act as a restraining factor that can hinder the market growth.
• Recent expiration of patents of drugs by major brands is a key challenge that can hamper the market growth during the forecast period.
• Rising initiatives to increase awareness of the disorder and rising number of people who are aware of early diagnostic of the disorder across the globe present key opportunities for the market expansion.

Scope of the Report

The report on the global epilepsy drug market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Market Segment Insights

Third generation anti-epileptics segment is anticipated to witness a rapid growth

On the basis of treatments, the global epilepsy drug market is divided into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third generation anti-epileptics segment is anticipated to witness a rapid growth during the forecast period attributed to the rising availability of these drugs and their deep penetration in the market. The third generation anti-epileptics include drugs such as lacosamide, eslicarbazepine, and retigabine. The first generation anti-epileptics include drugs such as carbamazepine, phenobarbital, valproate, primidone, and ethosuximide. Among these, carbamazepine is the most common drug prescribes by professionals for the treatment of partial and generalized seizures. These are key factors likely to boost the segment growth of the first generation. Meanwhile, the second generation anti-epileptics consist of drugs such as brivaracetam, perampanel, levetiracetam, and lamotrigine.

Get Free Sample Report

North America is expected to register a lucrative growth

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to register a lucrative growth during the forecast period attributed to ongoing research & development on a large scale, the launch of new anti-epileptic drugs, and the presence of favorable initiatives by various governments. However, the market of Asia Pacific is anticipated to expand at a robust growth rate in the coming years owing to the increasing level of awareness among the patients regarding the treatment of epilepsy and the presence of medical needs for highly unmet population in the region.  

Get Free Sample Report

Segments

Segments Covered in the Report

The global epilepsy drug market has been segmented on the basis of

Treatments

• First Generation Anti-Epileptics
• Second Generation Anti-Epileptics
• Third Generation Anti-Epileptics

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Sanofi S.A
• Cephalon, Inc.
• Johnson & Johnson
• Pfizer, Inc.
• Eisai Co., Ltd.
• Valeant Pharmaceuticals International, Inc.
• Novartis AG
• GlaxoSmithKline PLC.
• Abbott Laboratories, Inc.
• Sunovion Pharmaceuticals, Inc.
• UCB Pharma Ltd.

Competitive Landscape

Key players competing in the global epilepsy drug market are Sanofi S.A; Cephalon, Inc.; Johnson & Johnson; Pfizer, Inc.; Eisai Co., Ltd.; Valeant Pharmaceuticals International, Inc.; Novartis AG; GlaxoSmithKline PLC.; Abbott Laboratories, Inc.; Sunovion Pharmaceuticals, Inc.; and UCB Pharma Ltd. Many of these players have adopted business strategies such as the development of novel drugs, launching of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally.